Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 15, 2023 08:00 ET | Source: Ocuphire Pharma

Ocuphire Pharma Announces Financial Results for First Quarter 2023 and Provides Corporate Update

End-of-Phase 2 Meeting with FDA Anticipated in 2H 2023 to Confirm Phase 3 Regulatory Path for Oral APX3330 in Diabetic Retinopathy (DR) PDUFA date for Nyxol First Indication in Reversal of...
May 02, 2023 08:30 ET | Source: Ocuphire Pharma

Ocuphire Announces APX3330 and Nyxol® Data Presentations at ASCRS 2023 and Eyecelerator

FARMINGTON HILLS, Mich., May 02, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
April 25, 2023 08:00 ET | Source: Ocuphire Pharma

Ocuphire Provides Corporate Update and Reiterates Previous Guidance on Clinical Programs

PDUFA Date of September 28, 2023 Set for Nyxol® in its First Indication, Reversal of Pharmacologically-induced Mydriasis (RM); $10 Million Milestone Linked to Approval Oral APX3330 End of Phase 2...
April 21, 2023 08:00 ET | Source: Ocuphire Pharma

Ocuphire Appoints Rick Rodgers as Interim Chief Executive Officer

FARMINGTON HILLS, Mich., April 21, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
March 30, 2023 08:00 ET | Source: Ocuphire Pharma

Ocuphire Pharma Announces Financial Results for Fourth Quarter and Year Ended 2022 and Provides Corporate Update

Financial Profile Improved Markedly with Global License Agreement to Develop and Commercialize Nyxol for All Three Indications with Cash Runway into 2025 PDUFA Date of September 28, 2023 Set for...
March 23, 2023 08:00 ET | Source: Ocuphire Pharma

Ocuphire Announces APX3330 and Nyxol® Data Presentations at ARVO 2023 Annual Meeting

Oral Presentation to Feature Results from ZETA-1 Phase 2 Trial of APX3330 in Diabetic Retinopathy Patients Results from Phase 3 LYNX-1 Trial of Nyxol® in Dim Light Vision Disturbance to be...
February 16, 2023 08:30 ET | Source: Ocuphire Pharma

Ocuphire Announces APX3330 Phase 2 Data Presentations at Retina Meetings

Topline Data from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy Presented on February 11th at 20th Angiogenesis, Exudation, and Degeneration 2023 Meeting Topline Data from ZETA-1...
February 13, 2023 08:00 ET | Source: Ocuphire Pharma

Ocuphire Announces FDA Acceptance of New Drug Application and PDUFA Date of September 28, 2023 for Nyxol® Eye Drops for Reversal of Mydriasis

FARMINGTON HILLS, Mich., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
January 25, 2023 16:01 ET | Source: Ocuphire Pharma

Ocuphire Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA

Oral APX3330 Achieved Statistical Significance on a Key Pre-specified Secondary Endpoint of Preventing Clinically Meaningful Progression of Diabetic Retinopathy (DR) after 24 Weeks of Treatment ...
January 09, 2023 07:00 ET | Source: Ocuphire Pharma

Ocuphire Pharma Announces First Patient Enrolled in VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia

Nyxol® Eye Drops Potentially Offer Differentiated Mechanism of Action to Treat Age-Related Blurry Near Vision Launch of Presbyopia Phase 3 Program Supported by Positive Clinical Results that...